Hydrocortisone is the name for the hormone cortisol when supplied as a medication.
Clinical trials in ME/CFS[edit | edit source]
A 1998 double-blind, randomized, placebo-controlled trial found that low dose hydrocortisone led to significant improvement in subjective scores but concluded that the resulting degree of adrenal suppression precludes its practical use.
In 1999, the Institute of Psychiatry, London, did a randomized crossover trial, in which Simon Wessely was an author, where low dose hydrocortisone treatments given to patients with chronic fatigue syndrome were found to reduce fatigue scores and that 28% of patients in the treatment group had reductions in scores that brought them to or close to normal in the short term.
Learn more[edit | edit source]
See also[edit | edit source]
References[edit | edit source]
- McKenzie, R (September 1998). "Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial". JAMA. 280 (12): 1061–6.
- Cleare, AJ (February 1999). "Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial". Lancet. 353: 455–8.
- Blockmans, D (June 2003). "Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study". Am J Med. 114 (9): 736–41.
double blinded trial A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more: www.nottingham.ac.uk)